Visiopharm

The APPs are the product. Each is a deep learning algorithm performing a specific scoring or detection task on whole slide images, sold individually or as a diagnostic package. No scanner or assay hardware is manufactured; the alliance with Agilent validates the algorithms against Agilent's assays and instruments rather than bundling Visiopharm hardware. Remove the models and nothing remains.

The vendor is unusually explicit about where the machine stops. The APPs run fully automated with no manual interaction up to the point of pathologist review, and the company describes the output as objective decision support delivered for review rather than a diagnosis. The PD-L1 validation study is notable for testing both stand alone algorithm analysis and algorithm assisted interpretation as distinct conditions, which is a more honest framing of the autonomy question than most vendors offer. Automation is deep but terminates before sign out.

Individual APPs are described with real specificity, including what each measures and how output is ordered, for example metastasis detection ranking by largest diameter or total area depending on tumor type. Validation designs are disclosed at a useful level: the PD-L1 study compared manual assessment against stand alone and assisted analysis across three European sites with a multi reader reference score. Training data scale, model architecture, and head to head comparison against competing pathology AI are not published, so transparency is strong on validation design and lighter on model internals.

Better than vendor assertion, short of an outcomes literature. The PD-L1 APP rests on a clinical study across three European sites reporting substantial to near perfect agreement with a multi reader reference and high concordance with expert manual assessment. A named deployment at UMC Utrecht, integrated into a Sectra system, reports a clinical trial finding increased metastasis detection sensitivity plus roughly 35 percent time saved and reduced immunohistochemistry cost. Metastasis detection was verified on breast and colorectal data from three clinical sites for certification. Evidence is concordance and efficiency focused rather than patient outcome focused, which is typical for biomarker scoring but worth naming.

No specific PHI handling or data governance framework was located in the materials reviewed.

No HIPAA or BAA commitment was located. The clinical APPs are marketed for in vitro diagnostic use in the EU and UK rather than to US clinical buyers, so US business associate terms would need to be established directly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located. IVDR certification governs device safety and performance, not information security, so it does not substitute here.

Substantial European authorization, no US clinical clearance. The company describes the PD-L1 application as its ninth IVDR clearance and states it holds a full portfolio of clinical APPs certified under IVDR, which is a meaningful accumulation given IVDR's stricter evidence requirements. Its Agilent partner has stated publicly that Visiopharm is committed to pursuing FDA clearance, but no FDA clearance was located as of this review. One portfolio caveat a buyer should catch: the prostate APP is supplied by DeepBio and carries the older IVDD mark rather than IVDR. Graded C on the same basis as Aiforia, strong non US authorization without US clinical clearance.

Multi site validation across three clinical sites for both the PD-L1 and metastasis applications tests generalization beyond a single institution, which is a partial answer to the generalization question. No formal governance framework, ongoing monitoring commitment, or demographic subgroup analysis was located.

Integration into the pathology software environment is an explicit selling point rather than an afterthought. The company markets full integration into various image management and laboratory information systems with automated workflow requiring no manual interaction before review, and a named customer deployment runs inside a Sectra system. The Agilent alliance further embeds the APPs alongside Agilent assays and the Omnis platform. This is laboratory ecosystem integration; no EHR integration is claimed or applicable.

Specific hosting, tenancy, and data residency terms were not located in the materials reviewed. Deployment appears to run within the laboratory image management environment, but the vendor does not publish the terms.

No pricing is published. The per APP packaging does imply a modular purchasing model, and availability through Agilent as the Visiopharm Diagnostic Package gives a second procurement route, but no rates, bundle structure, or per case economics are disclosed. Buyers should establish whether they are licensing individual APPs or a portfolio, since narrow clearances mean coverage depends on exactly which algorithms are included.

Focused on anatomic pathology biomarker assessment, with clinical coverage across breast, lung, prostate, and colorectal cancer spanning HER2, Ki67, PD-L1, metastasis detection, and invasive tumor detection. Breadth comes from accumulating separately certified narrow algorithms, which means real coverage depends on the specific tumor type, antibody clone, and assay in use at a given laboratory rather than on the vendor name.